company background image
RGRX logo

RegeneRx Biopharmaceuticals OTCPK:RGRX Stock Report

Last Price

US$0.0014

Market Cap

US$2.1k

7D

0%

1Y

600.0%

Updated

05 Nov, 2024

Data

Company Financials

RegeneRx Biopharmaceuticals, Inc.

OTCPK:RGRX Stock Report

Market Cap: US$2.1k

RGRX Stock Overview

A biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration.

RGRX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

RegeneRx Biopharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for RegeneRx Biopharmaceuticals
Historical stock prices
Current Share PriceUS$0.0014
52 Week HighUS$0.062
52 Week LowUS$0.0004
Beta0
11 Month Change0%
3 Month Change0%
1 Year Change600.00%
33 Year Change-99.99%
5 Year Change-99.99%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Shareholder Returns

RGRXUS BiotechsUS Market
7D0%-1.4%-1.9%
1Y600.0%20.2%30.4%

Return vs Industry: RGRX exceeded the US Biotechs industry which returned 20.2% over the past year.

Return vs Market: RGRX exceeded the US Market which returned 30.4% over the past year.

Price Volatility

Is RGRX's price volatile compared to industry and market?
RGRX volatility
RGRX Average Weekly Movementn/a
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.9%

Stable Share Price: RGRX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine RGRX's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19823J. Finkelsteinwww.regenerx.com

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee’s Pharmaceutical Group and HLB Therapeutics.

RegeneRx Biopharmaceuticals, Inc. Fundamentals Summary

How do RegeneRx Biopharmaceuticals's earnings and revenue compare to its market cap?
RGRX fundamental statistics
Market capUS$2.11k
Earnings (TTM)-US$1.69m
Revenue (TTM)US$76.76k

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RGRX income statement (TTM)
RevenueUS$76.76k
Cost of RevenueUS$0
Gross ProfitUS$76.76k
Other ExpensesUS$1.77m
Earnings-US$1.69m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did RGRX perform over the long term?

See historical performance and comparison